The effectiveness of enzyme therapy in the comprehensive treatment of patients with chronic abacterial prostatitis (category IIIa)
https://doi.org/10.31549/2542-1174-2020-1-17-30
Abstract
Aim. To determine the possibility of increasing the effectiveness of treatment of patients with chronic abacterial prostatitis due to antisclerotic enzyme therapy; to prove its positive effect on urodynamics and microcirculation in the prostate.
Materials and methods. An open, prospective, randomized, comparative study included 60 patients with category IIIa chronic abacterial prostatitis. The participants were divided into two groups: the main group (MG, 31 patients) and the comparison group (CG, 29 patients). MG patients received the baseline therapy with the inclusion of Longidaza in the form of rectal suppositories, 3000 IU of the active substance three times a week, 20 suppositories per course. CG patients received identical baseline therapy in combination with rectal suppositories containing 500 mg of methyluracil — also 3 times a week, a total of 20 suppositories per course.
The effectiveness of treatment was evaluated by the dynamics of urination and microcirculation parameters, by a decrease in scores on the National Institutes of Health — Chronic Prostatitis Symptom Index (NIH-CPSI) scale and by a decrease in the number of white blood cells in the prostatic secretion. An excellent result implied a reduction in the total score on the NIH-CPSI scale to 14 or lower, the number of leucocytes in the prostate secretion — to 10 in the field of view or less, and an improvement in urodynamics and microcirculation by 40% or more from that of initial.
Results. In MG an excellent result was achieved in 21 patients (67.7%), in CG — in 14 patients (48.3%). A good result was observed in 9 patients (29.1%) of the MG and in 11 (37.9%) of the CG. Among patients receiving Longidaza there was no effect only in one case (3.2%), and four times as many in the CG (4 patients; 13.8%).
Conclusions. Antisclerotic enzyme therapy with Longidaza in the form of rectal suppositories contributed to a significant decrease in the intensity of symptoms of prostatitis, an improvement in urodynamic parameters and prostate microcirculation.
About the Authors
E. V. Kulchavenya
Novosibirsk Research Institute of Tuberculosis; Novosibirsk State Medical University
Russian Federation
Russian Federation
Kulchavenya Ekaterina Valeryevna — Dr. Sci. (Med.), Professor, Department of Tuberculosis, Novosibirsk State Medical University; Chief Researcher, Novosibirsk Research Institute of Tuberculosis.
52, Krasny Prospect, Novosibirsk, 630091
A. A. Baranchukova
Novosibirsk Research Institute of Tuberculosis; Novosibirsk State Medical University
Russian Federation
Baranchukova Anzhelika Anatolyevna — Cand. Sci. (Med.), Associate Professor, Department of Tuberculosis, Novosibirsk State Medical University; Doctor, Ultrasound Diagnostic Cabinet, Novosibirsk Research Institute of Tuberculosis.
Russian Federation
Baranchukova Anzhelika Anatolyevna — Cand. Sci. (Med.), Associate Professor, Department of Tuberculosis, Novosibirsk State Medical University; Doctor, Ultrasound Diagnostic Cabinet, Novosibirsk Research Institute of Tuberculosis.
References
1. Wong L., Hutson P.R., Bushman W. (2015). Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis. Prostate, 75 (1), 23–32. doi: 10.1002/pros.22886.
2. Nickel J.C., Roehrborn C.G., O’Leary M.P. et al. (2008). The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol., 54, 1379–1384.
3. Roehrborn C.G. (2006). Definition of at-risk patients: baseline variables. BJU Int., 97 (2), 7–11.
4. Bercovich E., Barabino G., Pirozzi-Farina F., Deriu M. (1999). A multivariate analysis of lower urinary tract ageing and urinary symptoms: the role of fibrosis. Arch. Ital. Urol. Androl., 71, 287–292.
5. Ma J., Gharaee-Kermani M., Kunju L. et al. (2012). Prostatic fibrosis is associated with lower urinary tract symptoms. J. Urol., 188, 1375–1381.
6. Kudryavtsev Yu.V., Chumakov A.M. (2000). Morphological changes in the prostate gland in chronic prostatitis. Modern aspects of diagnosis and treatment of chronic prostatitis: Conference Proc. Kursk, pp. 81–82. In Russ.
7. Wight T.N., Potter-Perigo S. (2011). The extracellular matrix: an active or passive player in fibrosis? Am. J. Physiol. Gastrointest. Liver. Physiol., 301, G950G955.
8. Gordon M.K., Hahn R.A. (2010). Collagens. Cell Tissue Res., 339, 247–257.
9. Frantz C., Stewart K.M., Weaver V.M. (2010). The extracellular matrix at a glance. J. Cell Sci., 123 (24), 4195–4200.
10. Kadler K.E., Baldock C., Bella J., Boot-Handford R.P. (2007). Collagens at a glance. J. Cell Sci., 120 (12), 1955–1958.
11. Rodes J. et al. (eds.) (2007). Textbook of Hepatology: From Basic Science to Clinical Practice. 3 rd ed. Malden Blackwell.
12. Thickett D.R., Poole A.R., Millar A.B. (2001). The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis Vasc. Diffuse Lung Dis., 18, 27–33.
13. Armstrong L., Thickett D.R., Mansell J.P. et al. (1999). Changes in collagen turnover in early acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med., 160, 1910–1915.
14. García-Bolao I., Lopez B., Macías A. et al. (2008). Impact of collagen type I turnover on the long-term response to cardiacresynchronization therapy. Eur. Heart J., 29, 898–906.
15. Selman M., Montaño M., Ramos C., Chapela R. (1986). Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. Thorax, 41, 355–359.
16. Kulchavenya E.V., Krasnov V.A., Mordyk A.V. (2015). Almanac for Extrapulmonary Tuberculosis. Novosibirsk: Sibprint, 247 p.
17. Wong L., Hutson P.R., Bushman W. (2014). Prostatic inflammation induces fibrosis in a mouse model of chronic bacterial infection. PLoS One, 9 (6): e100770. doi: 10.1371/journal.pone.0100770.
18. Cantiello F., Cicione A., Salonia A. et al. (2013). Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology, 81 (5), 1018–1023. doi: 10.1016/j.urology.2013.01.053.
19. Hu Y., Niu X., Wang G. et al. (2016). Chronic prostatitis/chronic pelvic pain syndrome impairs erectile function through increased endothelial dysfunction, oxidative stress, apoptosis, and corporal fibrosis in a rat model. Andrology, 4 (6), 1209–1216. doi: 10.1111/andr.12273.
20. Gorbunova E.N., Krupin V.N., Davydova D.A. (2011). Chronic inflammation and fibrosis as risk factors for prostatic intraepithelial neoplasia and prostate cancer. Modern Technologies in Medicine, 1, 79–83. In Russ.
21. Neimark A.I., Kiptilov A.V., Lapii G.A. (2015). Clinical and pathomorphological features of chronic prostatitis in chemical industry workers. Urologiia, 6, 68–73.
22. Zaitsev A.V., Pushkar D.Yu., Khodyreva L.A., Dudareva A.A. (2016). Bacterial prostatitis and prostatic fibrosis: modern view on the treatment and prophylaxis. Urologiia, 4, 114–121.
23. Filimonov P.N., Kulchavenya E.V. (2019). Consequences of excessive fibrosis formation in patients with chronic prostatitis. Russian Medical Journal, 27 (2), 39–41.
24. Pushkar D.Yu., Zaitsev A.V., Segal A.S. (2006). Longidaza in therapy of chronic prostatitis. Immunology, 27, 2, 119–121.
25. Pushkar D.Yu., Zaitsev A.V., Segal A.S. (2006). Longidase in the treatment of chronic prostatitis. Urologiia, 6, 26–28.
26. Avdoshin V.P., Andryukhin M.I., Pulbere S.A., Makarov O.V., Mikhaylikov T.G. (2012). Evaluation of the clinical efficacy of Longidaza ® in the comprehensive treatment of patients with chronic prostatitis. Effective Pharmacotherapy, 43, 22–25. In Russ.
27. Khodyreva L.A., Dudareva A.A., Karpov V.K. (2014). Longidaza in combination therapy of chronic prostatitis. Effective Pharmacotherapy, 32, 10–15. In Russ.
28. Avdoshin V.P., Andryukhin M.I., Mikhaylikov T.G. (2008). Experience of using enzyme therapy in the comprehensive treatment of chronic prostatitis. Consilium Medicum, 10, 4, 114–117. In Russ.
29. Avdoshin V.P., Mikhaylikov T.G., Andryuhin M.I., Olshanskaja E.V., Pulbere S.A. (2010). Evaluation of preparate Longidasa 3000 ME in complex treatment of patients with chronic prostatitis. Clinical Pharmacology and Therapy, 19, 4, 93–97.
30. Shatokhin M.N., Maltsev V.N., Konoplya A.I., Teodorovich O.V. (2010). Clinical and immunological efficiency of various medical forms longidaza at patients with the hyperplasia of the prostate in the combination to the chronic prostatitis. System Analysis and Management in Biomedical Systems, 9 (2), 327–331.
Review
For citations:
Kulchavenya E.V., Baranchukova A.A. The effectiveness of enzyme therapy in the comprehensive treatment of patients with chronic abacterial prostatitis (category IIIa). Journal of Siberian Medical Sciences. 2020;(1):17-30. https://doi.org/10.31549/2542-1174-2020-1-17-30
Views:
277
Email this article 